MedTrace Logo

Psoriatic Immune Response to Tildrakizumab

NCT05390515 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2023-08-29

No results posted yet for this study

Summary

This study aims to assess cutaneous and blood immune cell function of patients with psoriasis before and after initiation of treatment with the IL23 blocker, tildrakizumab.

Conditions

  • Psoriasis Vulgaris

Interventions

DRUG

Tildrakizumab Prefilled Syringe

IL-23 inhibitor

Sponsors & Collaborators

Principal Investigators

  • Raymond Cho, MD, PhD · University of California, San Francisco

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-01
Primary Completion
2025-09-01
Completion
2025-09-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05390515 on ClinicalTrials.gov